Subject: Re: DiFusion Follow-Up
From: "Eric Schwerin" <[email-masked]>
To: "Derrick Johns" <[email-masked]>
Cc: "Hunter Biden" <[email-masked]>
Date: Wed, 19 Nov 2014 11:38:26 -0500

Thanks, Derrick.

A lot of great information you have sent.  We’ll let you know if we need anything else.

Best,

Eric

Eric D. Schwerin
Rosemont Seneca Partners, LLC
1010 Wisconsin Ave., NW
Suite 705
Washington, DC 20007
(202) 333-1880
[email-masked]
P Consider the environment before printing this email.

On Nov 19, 2014, at 10:58 AM, Derrick Johns <[email-masked]> wrote:

> CONFIDENTIAL 
> 
> Just so you guys know you’re not spinning wheels.   Zimmer just bought Biomet for $13.5 billion…they know we are a threat…little old us…and looking to do a “pre emptive deal” see below - So is NuVasive whose emails I will send out behind this.   Our science is great, my connections are not…
> 
> The warrants will bring great value and Evan is working on a draft.
> 
> Derrick W. Johns
> CEO and Founder
> <1D44E4A7-AEC9-4D1E-A8ED-AAE1A3C8FDAD[21].png>
> www.difusiontech.com
> 
> "All Truths are easy to understand once discovered, 
>              the point is to discover them”  - Galileo
> 
> (512) 863-7777 o
> (512) 284-3338 c
> 
> 
> 
> From: "Smyth, Linda" <[email-masked]>
> Date: Tuesday, November 18, 2014 at 10:29 AM
> To: Derrick Johns <[email-masked]>
> Cc: "Cloar, Jim" <[email-masked]>
> Subject: RE: DiFusion Follow-Up
> 
> Hi Derrick,
>  
> We appreciate your taking the time to meet with us during NASS.  We are looking forward to receiving the instructions for the clinical data room.  I will send you a confirmation email as soon as we receive it. 
>  
> Best,
>  
> Linda
>  
> From: Derrick Johns [mailto:[email-masked]] 
> Sent: Monday, November 17, 2014 10:07 PM
> To: Cloar, Jim; Smyth, Linda
> Subject: DiFusion Follow-Up
> Importance: High
>  
> Jim and Linda,
>  
> Thank for taking to the time to learn more about our science and corporate direction at NASS.   To make further evaluation easier for you, I have asked our counsel to add you to our clinical data room with others instead of doing an email dump.   We have not asked any strategics for NDA’s given our IP and will not require one for Biomet.
>  
> As we discussed I think Zimmer Biomet could especially benefit from CleanFuze and the contracting leverage an antimicrobial / osteoconductive material would provide against bigger players like Depuy across spine and total joint.   We will begin our PMS for “fusion equivalency” with Professor Meisel, MD, Ph.D. in Q1 upon receipt of our SBIR Phase II Grant.  That would be the window in which our Board would want to be closing any milestone or First Right deals to avoid engaging VC’s in front of FDA clearance.(Q3 2015 FDA Clearance, Master File Submitted 11/09/14 – Pre Sub Meeting complete).  That would only require a small capital infusion in January and not detract resources from your current closing.
>  
> You will both receive invites to our scientific data room shortly.   Again, it was a pleasure meeting you both.
>  
> Derrick W. Johns
> CEO and Founder
> www.difusiontech.com
>  
> "All Truths are easy to understand once discovered, 
>              the point is to discover them”  - Galileo
>  
> (512) 863-7777 o
> (512) 284-3338 c
>  
>  
> <1D44E4A7-AEC9-4D1E-A8ED-AAE1A3C8FDAD[21].png>